Nobody has filed for crossing 5%. That is a fact, not missing data.
OPXS planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
Executive pay vs shareholder return
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$434.9K
$434.9K
$323.2K
+74%
n/a
2024
$551.1K
$688.9K
$341.9K
+81%
n/a
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
Each figure here is a federal filing, dated the day it went public, so you can test what was knowable then.
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$39.8M
four quarters, 2025-06-30 to 2026-06-28
Revenue, TTM OPXS
FY Sep 2025
$41.3M
FY Sep 2024
$34.0M
FY Oct 2023
$25.7M
FY Oct 2022
$22.4M
FY Oct 2021
$18.2M
Jun 2026
$9.7M
Mar 2026
$9.6M
Dec 2025
$9.1M
Sep 2025
$11.3M
Jun 2025
$11.1M
Mar 2025
$10.7M
Dec 2024
$8.2M
Sep 2024
$9.4M
At each fiscal year end
Single quarter
Net margin, TTM
+9.8%
net income over revenue, 2025-06-30 to 2026-06-28
Net margin, TTM OPXS
FY Sep 2025
+12.5%
FY Sep 2024
+11.1%
FY Oct 2023
n/a
FY Oct 2022
+5.7%
FY Oct 2021
+11.7%
Jun 2026
+13.2%
Mar 2026
+13.9%
Dec 2025
+2.6%
Sep 2025
+9.1%
Jun 2025
+13.6%
Mar 2025
+16.5%
Dec 2024
+10.3%
Sep 2024
+10.7%
At each fiscal year end
Single quarter
Free cash flow, TTM
$1.5M
operating cash flow minus capex, 2025-06-30 to 2026-06-28
Free cash flow, TTM OPXS
FY Sep 2025
$6.4M
FY Sep 2024
$1.1M
FY Oct 2023
-$672.0K
FY Oct 2022
$1.8M
FY Oct 2021
$207.0K
Jun 2026
$2.1M
Mar 2026
-$1.6M
Dec 2025
-$548.0K
Sep 2025
$1.5M
Jun 2025
$1.4M
Mar 2025
$1.1M
Dec 2024
$2.5M
Sep 2024
$545.0K
At each fiscal year end
Single quarter
Debt to equity
n/a
no debt line filed
Debt to equity OPXS
FY Sep 2025
n/a
FY Sep 2024
n/a
FY Oct 2023
n/a
FY Oct 2022
n/a
FY Oct 2021
n/a
Jun 2026
n/a
Mar 2026
n/a
Dec 2025
n/a
Sep 2025
n/a
Jun 2025
n/a
Mar 2025
n/a
Dec 2024
n/a
Sep 2024
n/a
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
no debt line filed
Cash flow to debt OPXS
FY Sep 2025
n/a
FY Sep 2024
n/a
FY Oct 2023
n/a
FY Oct 2022
n/a
FY Oct 2021
n/a
Jun 2026
n/a
Mar 2026
n/a
Dec 2025
n/a
Sep 2025
n/a
Jun 2025
n/a
Mar 2025
n/a
Dec 2024
n/a
Sep 2024
n/a
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+15.3%
TTM net income over average of 2025-06-29 and 2026-06-28
Return on equity OPXS
FY Sep 2025
+23.9%
FY Sep 2024
+22.4%
FY Oct 2023
n/a
FY Oct 2022
+9.1%
FY Oct 2021
+14.4%
Jun 2026
+15.3%
Mar 2026
+17.2%
Dec 2025
+20.4%
Sep 2025
+23.9%
Jun 2025
+25.1%
Mar 2025
+25.7%
Dec 2024
+23.8%
Sep 2024
+22.4%
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+12.6%
TTM net income over average of 2025-06-29 and 2026-06-28
Return on assets OPXS
FY Sep 2025
+18.5%
FY Sep 2024
+15.8%
FY Oct 2023
n/a
FY Oct 2022
+6.5%
FY Oct 2021
+10.3%
Jun 2026
+12.6%
Mar 2026
+14.1%
Dec 2025
+16.5%
Sep 2025
+18.5%
Jun 2025
+19.0%
Mar 2025
+19.1%
Dec 2024
+17.7%
Sep 2024
+15.8%
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
no debt line filed
Return on invested capital OPXS
FY Sep 2025
n/a
FY Sep 2024
n/a
FY Oct 2023
n/a
FY Oct 2022
n/a
FY Oct 2021
n/a
Jun 2026
n/a
Mar 2026
n/a
Dec 2025
n/a
Sep 2025
n/a
Jun 2025
n/a
Mar 2025
n/a
Dec 2024
n/a
Sep 2024
n/a
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+19.9%
operating income (EBIT proxy) over average of 2025-06-29 and 2026-06-28 minus current liabilities
Return on capital employed OPXS
FY Sep 2025
+31.0%
FY Sep 2024
+24.9%
FY Oct 2023
+16.7%
FY Oct 2022
+9.7%
FY Oct 2021
-2.9%
Jun 2026
+19.9%
Mar 2026
+23.0%
Dec 2025
+26.9%
Sep 2025
+31.0%
Jun 2025
+28.8%
Mar 2025
+28.8%
Dec 2024
+26.7%
Sep 2024
+24.9%
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
17.56x
close 2026-10-26 over four quarters of diluted EPS, 2025-06-30 to 2026-06-28
P/E, trailing OPXS
FY Sep 2025
17.68x
FY Sep 2024
13.65x
FY Oct 2023
12.22x
FY Oct 2022
16.93x
FY Oct 2021
12.38x
Jun 2026
23.70x
Mar 2026
22.93x
Dec 2025
21.65x
Sep 2025
17.68x
Jun 2025
15.32x
Mar 2025
7.89x
Dec 2024
11.51x
Sep 2024
13.65x
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
n/a
no debt line filed
Enterprise value OPXS
FY Sep 2025
n/a
FY Sep 2024
n/a
FY Oct 2023
n/a
FY Oct 2022
n/a
FY Oct 2021
n/a
Jun 2026
n/a
Mar 2026
n/a
Dec 2025
n/a
Sep 2025
n/a
Jun 2025
n/a
Mar 2025
n/a
Dec 2024
n/a
Sep 2024
n/a
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+2.2%
TTM free cash flow over market value at close 2026-10-26
FCF yield OPXS
FY Sep 2025
+7.1%
FY Sep 2024
+2.1%
FY Oct 2023
-2.4%
FY Oct 2022
+8.4%
FY Oct 2021
+1.2%
Jun 2026
+1.6%
Mar 2026
+0.8%
Dec 2025
+3.5%
Sep 2025
+7.1%
Jun 2025
+6.9%
Mar 2025
+9.9%
Dec 2024
+2.9%
Sep 2024
+2.1%
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing EPS growth -28%, PEG needs growth
PEG, trailing OPXS
FY Sep 2025
0.51x
FY Sep 2024
0.22x
FY Oct 2023
0.10x
FY Oct 2022
n/a
FY Oct 2021
0.27x
Jun 2026
n/a
Mar 2026
n/a
Dec 2025
3.30x
Sep 2025
0.51x
Jun 2025
0.67x
Mar 2025
0.22x
Dec 2024
0.27x
Sep 2024
0.22x
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
OPXS ranks highest on growth (83rd percentile) and profitability (82nd), and lowest on risk and compliance (67th), among Industrials peers.
Profitability
82
Inputs
Return on equity+15.3% · 68 pct, sector of 198
Return on assets+12.6% · 91 pct, sector of 224
Return on invested capitalno debt line filed
Return on capital employed+19.9% · 89 pct, sector of 195
Growth
83
Inputs
Revenue growth, YoY+21.6% · 83 pct, sector of 254
Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Risk and compliance
67
Inputs
Short interest, % of float+0.6% · 87 pct, sector of 269
Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
New text in Risk Factors, latest 10-K+11.5% · 47 pct, sector of 197
4 not measured: Financial health, Insider conviction, Institutional and government, US patents
Financial health needs 1 of 2 inputs, 0 present: no debt line filed
Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
Institutional and government needs 1 of 4 inputs, 0 present: fewer than five funds report holding it; no Congress trades in 365 days; no federal contracts in 180 days; no lobbying filings in the last four quarters
US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet
3 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
No password to create and no card required. We store your email address, your watchlist and your preferences, nothing else.
PRIVACY & COOKIES
We track filings, not you.
Essential cookies keep you signed in and remember this choice.
Google Analytics 4 and Microsoft Clarity load only if you allow them here; they
count visits and record how pages are used. We run no advertising and never sell
data. Details in the privacy policy. Change this any time
via "Cookie settings" in the footer.